Introduction The approval of antifibrotic agents nintedanib and pirfenidone revolutionized the management of idiopathic pulmonary fibrosis (IPF). These treatments showed acceptable tolerability in randomized-clinical trials; however, they have been associated with a spectrum of potential side effects which require careful assessment of risks and benefits in the individual patient before commencing and during antifibrotic therapy. Areas covered The accrued evidence on safety of nintedanib and pirfenidone is summarized, from the first randomized clinical trials to the open-label extension studies and post-marketing clinical experiences which helped clarify the long-term tolerability of these drugs. Expert opinion The data collected over the last years confirmed the comparable tolerability profile of nintedanib and pirfenidone. The physician's assessment of expected side effects may help decide the optimal first-line therapy for the individual patient. Patient's counseling during treatment remains essential to manage emerging adverse events and eventually inform the decision of drug discontinuation.

Sgalla, G., Comes, A., Richeldi, L., An updated safety review of the drug treatments for idiopathic pulmonary fibrosis, <<EXPERT OPINION ON DRUG SAFETY>>, 2021; 20 (9): 1035-1048-1048. [doi:10.1080/14740338.2021.1921143] [http://hdl.handle.net/10807/187350]

An updated safety review of the drug treatments for idiopathic pulmonary fibrosis

Sgalla, Giacomo
Primo
;
Comes, Alessia
Secondo
;
Richeldi, Luca
Ultimo
2021

Abstract

Introduction The approval of antifibrotic agents nintedanib and pirfenidone revolutionized the management of idiopathic pulmonary fibrosis (IPF). These treatments showed acceptable tolerability in randomized-clinical trials; however, they have been associated with a spectrum of potential side effects which require careful assessment of risks and benefits in the individual patient before commencing and during antifibrotic therapy. Areas covered The accrued evidence on safety of nintedanib and pirfenidone is summarized, from the first randomized clinical trials to the open-label extension studies and post-marketing clinical experiences which helped clarify the long-term tolerability of these drugs. Expert opinion The data collected over the last years confirmed the comparable tolerability profile of nintedanib and pirfenidone. The physician's assessment of expected side effects may help decide the optimal first-line therapy for the individual patient. Patient's counseling during treatment remains essential to manage emerging adverse events and eventually inform the decision of drug discontinuation.
Inglese
Sgalla, G., Comes, A., Richeldi, L., An updated safety review of the drug treatments for idiopathic pulmonary fibrosis, <<EXPERT OPINION ON DRUG SAFETY>>, 2021; 20 (9): 1035-1048-1048. [doi:10.1080/14740338.2021.1921143] [http://hdl.handle.net/10807/187350]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/187350
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 4
social impact